Evidence map›Paper›PMID 40073103›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2025

SYK negatively regulates ITAM-mediated human NK cell signaling and CD19-CAR NK cell efficacy.

Alberto J Millan, Vincent Allain, Indrani Nayak, Jeremy B Libang, Lilian M Quijada-Madrid, Janice S Arakawa-Hoyt, Gabriella Ureno, Allison Grace Rothrock, Avishai Shemesh, Oscar A Aguilar and 3 more

Erratum issuedAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. NK cells in HPV-related tumorigenesis: mechanisms and clinical applications.Frontiers in cellular and infection microbiology · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Alberto J MillanDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0003-1186-7219
Vincent AllainDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0002-1068-7892
Indrani NayakSteve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, College of Medicine, The Ohio State University, Columbus, OH, United States.ORCID 0000-0002-4257-8965
Jeremy B LibangDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, United States.
Lilian M Quijada-MadridDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, United States.
Janice S Arakawa-HoytDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0003-0969-1082
Gabriella UrenoDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0009-0005-1315-2278
Allison Grace RothrockDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID 0009-0002-6734-6180
Avishai ShemeshDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0002-6934-7155
Oscar A AguilarDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0002-7990-8745
Justin EyquemDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0001-8262-1190
Jayajit DasSteve and Cindy Rasmussen Institute for Genomic Medicine, Nationwide Children's Hospital, College of Medicine, The Ohio State University, Columbus, OH, United States.ORCID 0000-0001-9649-4698
Lewis L LanierDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0003-1308-3952

Funding

MOLECULAR AND CELLULAR IMMUNOLOGYT32AI007334 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CYSTER, JASON G · 1988 to 2023
$11.0M
Mechanistic Modeling of Cellular SystemsR24GM137787 · NIGMS · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI Pedro Mendes, Ion I. Moraru · 2020 to 2026
$8.9M
Restorative practice in repairing harm and promoting safe and inclusive practices in the laboratory.T32GM136547 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adrian Erlebacher, Anita Sil · 2020 to 2026
$4.5M
Modeling Antibody-induced Immune Responses by NK cells in Mice and Humans (Resubmission 1)R01AI146581 · NIAID · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI DAS, JAYAJIT · 2020 to 2025
$2.3M
National Institute for General Medical SciencesNIAID NIH HHS R01 AI146581NIAID NIH HHS T32 AI007334NIGMS NIH HHS R24 GM137787NIGMS NIH HHS T32 GM136547NIH HHS R01AI146581NIH HHS R24 GM137787Parker Institute for Cancer ImmunotherapyVirtual Cell
6 · The paper itself

Abstract

Natural killer (NK) cells express activating receptors that signal through ITAM (immunoreceptor tyrosine-based activation motif)-bearing adapter proteins. The phosphorylation of each ITAM creates binding sites for SYK and ZAP70 protein tyrosine kinases to propagate downstream signaling including the induction of Ca2+ influx. While all immature and mature human NK cells coexpress SYK and ZAP70, clonally driven memory or adaptive NK cells can methylate SYK genes, and signaling is mediated exclusively using ZAP70. Here, we examined the role of SYK and ZAP70 in a clonal human NK cell line KHYG1 by CRISPR-based deletion using a combination of experiments and mechanistic computational modeling. Elimination of SYK resulted in more robust Ca2+ influx after crosslinking of the CD16 and NKp30 receptors and enhanced phosphorylation of downstream proteins, whereas ZAP70 deletion diminished these responses. By contrast, ZAP70 depletion increased proliferation of the NK cells. As immature T cells express both SYK and ZAP70 and mature T cells often express only ZAP70, we transduced the human Jurkat cell line with SYK and found that expression of SYK increased proliferation but diminished T cell receptor-induced Ca2+ flux and activation. We performed transcriptional analysis of the matched sets of variant Jurkat and KHYG1 cells and observed profound alterations caused by SYK expression. As depletion of SYK in NK cells increased their activation, primary human NK cells were transduced with a CD19-targeting chimeric antigen receptor and were CRISPR edited to ablate SYK or ZAP70. Deletion of SYK resulted in more robust cytotoxic activity and cytokine production, providing a new therapeutic strategy of NK cell engineering for cancer immunotherapy.

Indexed as

Antigens, CD19Immunoreceptor Tyrosine-Based Activation MotifImmunotherapy, AdoptiveKiller Cells, NaturalReceptors, Chimeric AntigenSyk KinaseHumansPhosphorylationSignal TransductionZAP-70 Protein-Tyrosine KinaseAntigens, CD19CD19 molecule, humanReceptors, Chimeric AntigenSyk KinaseSYK protein, humanZAP70 protein, humanZAP-70 Protein-Tyrosine Kinasecell activationcell surface moleculesFc receptorshumannatural killer cellsT cells

Identifiers

PMID40073103
PMCPMC11952873

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.